Here's Why This Obesity Drug Company's Share Price Soared Today

Key Points The company's lead drug candidate is in a phase 3 trial, and enrollment is progressing well. The drug is also being tested in oral formulation, and there's plenty of value in Viking's pipeline. 10 stocks we like better than Viking Therapeutics › In common with many other small-cap biotech stocks, Viking Therapeutics' (NASDAQ: VKTX) share price tends to be volatile as investors react to the ebb and flow of news from the company. Today was an up day with the stock rising more than 10% by 1 ...